

1 **Management and outcomes of myelomeningocele-associated**
2 **hydrocephalus in low- and middle-income countries: a systematic**
3 **review and meta-analysis protocol**

4 Berjo Dongmo Takoutsing^{1-2*}, Alvaro Yanez Touzet^{3*}, Jay J. Park⁴, Seong Hoon
5 Lee⁵, Emily R. Bligh^{6,7}, Abdullah Egiz⁸, Conor S. Gillespie⁹, Anthony Figaji¹⁰⁻¹¹, On
6 behalf of the Neurology and Neurosurgery Interest Group

7

8 ¹Faculty of Health Sciences, University of Buea, Buea, Cameroon

9 ²Research Department, Association of Future African Neurosurgeons, Yaounde,
10 Cameroon

11 ³School of Medical Sciences, Faculty of Biology, Medicine and Health, University of
12 Manchester, Manchester, United Kingdom

13 ⁴Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom

14 ⁵Academic Critical Care & Neurosurgery, Aberdeen Royal Infirmary, Aberdeen,
15 United Kingdom

16 ⁶Surgical Specialties, The Queen Elizabeth University Hospital, Glasgow, United
17 Kingdom

18 ⁷Academic Foundation Programme, The University of Glasgow, Glasgow, United
19 Kingdom

20 ⁸School of Medicine, University of Central Lancashire, Preston, United Kingdom

21 ⁹Institute of Systems, Molecular and Integrative Biology, University of Liverpool,
22 Liverpool, United Kingdom

23 ¹⁰Division of Paediatric Neuroscience (Neurosurgery), School of Child and
24 Adolescent Health, University of Cape Town, Cape Town, South Africa

25 ¹¹Red Cross Children's Hospital, Klipfontein Road, 7700 Rondebosch, Cape Town,
26 South Africa

27 **Correspondence to:** Alvaro Yanez Touzet;

28 alvaro.yaneztouzet@student.manchester.ac.uk

29 *These authors contributed equally.

30

31 **PROSPERO registration number:** CRD42021285850

32

33 **Word count:** 1,860

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276320>; this version posted November 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

34 **ABSTRACT**

35 **Introduction:** Hydrocephalus and myelomeningocele (MMC) place disproportionate
36 burdens of disease on low and middle-income countries (LMICs). MMC-associated
37 hydrocephalus and its sequelae result in a spectrum of severely devastating clinical
38 manifestations, for which LMICs are disproportionately unprepared in terms of human,
39 capital, and technological resources. This study aims to review and compare the
40 management and outcomes of infant MMC-associated hydrocephalus in LMICs and
41 high-income countries.

42

43 **Methods and analysis:** This systematic review and meta-analysis will follow the
44 PRISMA 2020 guidelines. The following databases will be searched without
45 restrictions on language, publication date, or country of origin: EMBASE, MEDLINE,
46 The Cochrane Library, Global Index Medicus, African Journals Online, and SciELO.
47 All peer-reviewed studies of primary data reporting management and outcomes of
48 infant MMC-associated hydrocephalus will be included. Where high-quality
49 homogeneous studies exist, meta-analyses will be conducted to compare the
50 management and outcomes of MMC-associated hydrocephalus across
51 socioeconomic and geographic regions of the world. The primary outcome will be
52 treatment failure of the first-line hydrocephalus treatment, which we defined
53 operationally as the performance of a second intervention for the same reason as the
54 first. Secondary outcomes include time to failure, rates of mortality, and postoperative
55 complications.

56

57 **Ethics and dissemination:** Ethical approval was not applicable because this study
58 does not involve human participants. Dissemination strategies will include publication
59 in a peer-reviewed journal, oral and poster presentations at conferences, and an
60 interactive web application to facilitate interaction with the findings and promote the
61 discussion and sharing of findings on social media.

62

63 **PROSPERO registration number:** CRD42021285850

64

65 **Word count:** 245

66 **ARTICLE SUMMARY**

67 **Strengths and limitations of this study**

- 68 ● This review focuses on multiple treatment modes of a well-defined disease
69 population.
- 70 ● Six electronic databases that are commonly used across both high- and low-
71 income countries will be searched.
- 72 ● No restrictions on language, location, or publication date were placed during
73 screening.
- 74 ● Unpublished studies will not be sought.
- 75 ● The representativeness of the sample will rely on the quality of reporting of
76 myelomeningocele-associated hydrocephalus in the literature.
- 77 ● Only one operational definition of treatment failure—'the performance of a
78 second intervention for the same reason as the first'—will be sought.
- 79 ● An interactive web application dashboard will be developed to facilitate the
80 transparent interaction with our methods and findings and promote scientific
81 discussion and scrutiny.

82

83 **Keywords:** Systematic Review; Meta-Analysis; Hydrocephalus; Meningomyelocele;
84 Infant; Developing Countries; Outcome and Process Assessment, Health Care

85

86 INTRODUCTION

87 Hydrocephalus places a disproportionate burden of disease on low- and middle-
88 income countries (LMICs) (1, 2). It affects approximately 1 in 1,000 infants worldwide,
89 but its incidence may exceed 200,000 cases per year in developing regions like sub-
90 Saharan Africa (3). Myelomeningocele (i.e., meningomyelocele or open spina bifida;
91 MMC) is a common and severe spinal aetiology and constitutes a significant proportion
92 of this population (4-6). Its prevalence also varies by geography but approximates 113
93 cases per 100,000 births in LMICs (7, 8), reaching 77–610 and 700 cases per 100,000
94 births in South Africa and Nigeria, respectively. These disorders result in a spectrum
95 of clinical manifestations, among which MMC-associated hydrocephalus is one of the
96 most common and debilitating (4, 9, 10).

97

98 In LMICs, the incidence of MMC-associated hydrocephalus is high and can affect as
99 many as 75% of cases (11, 12). Times to diagnoses and treatment are often delayed
100 in these settings and, if treatment is not promptly initiated, most patients do not survive
101 beyond infancy (4). Treatment may involve surgery, which is prone to significant
102 morbidity and mortality, particularly in low-resource settings (1, 3). Intervening at the
103 earliest stage with the best possible treatment remains, therefore, a crucial step in the
104 management of MMC-associated hydrocephalus.

105

106 Ventriculoperitoneal (VP) shunts are the current standard of treatment in LMICs (1).
107 Increasingly, patients are being treated with endoscopic third ventriculostomy (ETV)
108 or combinations of ETV and choroid plexus cauterization (CPC), whose success rates
109 and perceptions are variable (1, 3, 4, 9). Although ETV/CPCs were first developed and
110 validated in LMICs as the primary management for MMC-associated hydrocephalus,
111 there remains limited aggregated data regarding their outcomes in the very countries
112 these procedures were developed in. As such, the practice and outcomes of these
113 techniques in LMICs warrant systematic review and meta-analysis. Previous work has
114 examined the management and outcomes of hydrocephalus in HICs and LMICs (13,
115 14) albeit in unstratified medical subject headings (MeSH) age groups and aetiologies.

116

117 STUDY AIMS AND OBJECTIVES

118 Aim

119 This study aims to review and compare the management and outcomes of MMC-
120 associated hydrocephalus in infants across countries and treatment modes.

121

122 **Objectives**

123 To review and compare:

- 124 1. The first- and second-line use of VP shunts, combinations of ETV and CPC,
125 and conservative management;
- 126 2. The rates and times to treatment failure of VP shunts, combinations of ETV and
127 CPC, and conservative management; and
- 128 3. Measures of mortality and postoperative complications of VP shunts,
129 combinations of ETV and CPC, and conservative management.

130

131 **Review questions**

132 Primary question:

- 133 1. What are the rates of failure of VP shunts, ETV, combinations of ETV and CPC,
134 and conservative treatments in infant MMC-associated hydrocephalus?

135

136 Secondary questions:

- 137 2. What are the most frequent first- and second-line treatments in the
138 management of infant MMC-associated hydrocephalus?
- 139 3. What is the time to failure of VP shunts, ETV, combinations of ETV and CPC,
140 and conservative treatments in infant MMC-associated hydrocephalus?
- 141 4. What are the mortality and postoperative complication rates of VP shunts, ETV,
142 combinations of ETV and CPC, and conservative treatments in infant MMC-
143 associated hydrocephalus?
- 144 5. Are the management and outcomes of the MMC associated with the failure of
145 the hydrocephalus treatment?

146

147 Subgroup analyses by country and treatment mode are planned (further details in
148 **Methods** section). The primary outcome will be the rate of treatment failure of the first-
149 line hydrocephalus treatment. Secondary outcomes include: time to failure, rates of
150 mortality, and postoperative complications. Operational definitions of outcomes are
151 provided in the **Methods**.

152

153 Due to its historical standing as the local standard of treatment, our principal
154 hypothesis is that:

155 H₁: VP shunts have the lowest rates of treatment failure in the infant MMC-
156 associated hydrocephalus population.

157

158 Secondary hypotheses include:

159 H₂: VP shunts are the most frequently used first-line treatment and have the lowest
160 mortality and complication rates.

161 H₃: Resource constrained environments are associated with late/worse MMC
162 presentation amongst infants

163 H₄: Late/worse MMC presentation is associated with high MMC treatment failure,
164 mortality, and complication rates.

165 H₅: MMC complication rates are associated with hydrocephalus treatment failure,
166 mortality, and complication rates.

167

168 **METHODS**

169 This systematic review will be conducted following the guidelines outlined by the
170 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
171 2020 statement (15).

172

173 **Search**

174 A search strategy was developed to identify research articles on MMC-associated
175 hydrocephalus. This was adapted from [McCarthy et al., 2019](#), and consisted of
176 synonyms of 'hydrocephalus' and 'myelomeningocele' (**Supplementary Table 1**).

177 The search was run on the following electronic databases, from inception until 5
178 October 2021: EMBASE, MEDLINE, The Cochrane Library, Global Index Medicus,
179 African Journals Online, and ScieLO. No restrictions on language, location, or
180 publication date were placed, and unpublished studies will not be sought. Searches in
181 all databases will be re-run prior to final analysis.

182

183 **Study selection**

184 ***Types of studies***

185 We will include articles published in peer-reviewed journals with any of the following
186 designs: original research, trials, cross-sectional and cohort studies, multiple case

187 reports (i.e., >1 case), and case series. Opinion pieces, comments, letters, guidelines,
188 editorials, single-case reports, reviews, meta-analyses, and qualitative studies will be
189 excluded, as well as articles published in non-peer-reviewed journals.

190

191 ***Country income level***

192 We will include studies whose data were collected in low-, lower-middle-, upper-
193 middle-, and high-income economies, according to the World Bank Country and
194 Lending Groups (16). Studies from high-income economies will be used as
195 comparators. Studies whose data cannot be traced to one particular country will be
196 excluded.

197

198 ***Types of participants***

199 All studies of infants aged 2 years or younger with a clinical or imaging diagnosis of
200 MMC-associated hydrocephalus will be included. Non-infants (i.e., >2 years) will be
201 excluded, as will infants with diagnoses of lipomyelomeningocele, spina bifida
202 occulta, or unspecified spina bifida, regardless of association with hydrocephalus.

203

204 ***Types of interventions***

205 Studies of infants who have undergone either surgical or conservative treatment for
206 hydrocephalus will be included. Surgical treatment includes VP shunting, ETV,
207 combined ETV and CPC, combined VP shunting and ETV, and combined VP shunting,
208 ETV, and CPC. We defined conservative treatment as non-surgical medical or
209 pharmacological treatment. Studies of infants who underwent treatment for MMC, but
210 not hydrocephalus, will be excluded, as will patients who received neither surgical nor
211 conservative interventions.

212

213 ***Types of outcome measures***

214 We will include studies of primary data reporting measures of treatment failure. In this
215 review, treatment failure will be operationally defined as the performance of a second
216 intervention for the same reason as the first. Studies reporting measures of mortality,
217 morbidity, postoperative complications, and follow-up duration will also be included for
218 secondary analysis. Post-operative complications will be defined as the unfavourable
219 result of an intervention that did not result in treatment failure, and mortality as either
220 'intra-operative', if death occurred during a procedure, or 'perioperative', if it occurred

221 within 30 days of surgery. For conservative treatments, mortality will encompass
222 deaths that occurred within 30 days of administration.

223

224 **Outcomes**

225 The primary outcome of our study will be the rate of treatment failure for the first-line
226 hydrocephalus treatment. Secondary outcomes will include time to failure, rates of
227 mortality, and postoperative complications.

228

229 **Study selection**

230 Search results will be uploaded to Rayyan (<https://www.rayyan.ai>) to facilitate de-
231 duplication and independent, blinded screening (17). First, titles and abstracts will be
232 screened by two independent reviewers against the inclusion criteria, and the eligibility
233 of the selected abstracts will be determined by reading the full texts. Unless otherwise
234 stated, conflicts will be resolved through discussion and, where consensus cannot be
235 achieved, through arbitration by the senior author (AF).

236

237 **Data extraction**

238 Two reviewers will independently extract and check the data extracted from the
239 included studies using a standardised extraction proforma in Google Sheets
240 (**Supplementary Table 2**). Any disputes will be settled by a third reviewer (BDT, AYT,
241 or AF). Data items will include information on study and sample characteristics;
242 vertebral level of MMC and aetiology of hydrocephalus; clinical presentation and
243 method of diagnosis; treatment mode, timing, and follow-up; and primary and
244 secondary outcomes. If data is insufficiently provided in the full text, we will contact
245 the corresponding author to request for the missing information and wait up to two
246 months for a response. Following correspondence, all available data will be reported
247 and studies with missing data will not be eligible for inclusion in the meta-analysis. All
248 data will be recorded and stored in a spreadsheet.

249

250 **Risk of bias assessment**

251 Included studies will be assessed for risk of bias by two independent reviewers of the
252 extraction team. Randomised studies will be assessed using Version 2 of the
253 Cochrane risk-of-bias tool for randomised trials (RoB 2) (18). Non-randomised studies
254 will be assessed using the ROBINS I tool (19). Risk of bias assessment will be used

255 during the analysis and results presented in terms of the primary and secondary
256 objectives of this study.

257

258 **Data analysis**

259 Following extraction, data will be transferred to Python for analysis. Screening results
260 will be presented using a PRISMA flow diagram. Study and sample characteristics will
261 then be summarised using descriptive statistics; these may include: vertebral level of
262 MMC; aetiology of hydrocephalus; method of diagnosis; treatment mode; indication
263 for surgery (if surgical management); timing, and follow-up; and primary and
264 secondary outcomes.

265

266 The use, failure, and mortality measures of VP shunts, combinations of ETV and
267 CPC, and conservative management will then be meta-analysed. Although meta-
268 analyses are planned, these will only become apparent after data extraction is
269 complete. Publication bias will be assessed through the use of funnel plots and
270 Egger's test (20). If asymmetry is found in the funnel plot, the Trim-and-Fill method will
271 be used to account for any potential publication bias (21). The overall estimates and
272 95% confidence intervals will be obtained using random-effects models as per
273 established methods (22). Cochran's Q test ($P < 0.10$) and the I^2 statistic will be used
274 to assess heterogeneity among studies (23). Unless otherwise stated, the statistical
275 significance will be set at $P < 0.05$, and comparisons to high-income economies will
276 be drawn.

277

278 Mortality, failure, and complication rates will however vary with hydrocephalus
279 aetiology, age, mode of treatment, characteristics of MMC, socioeconomic region and,
280 crucially, duration of follow-up. Therefore, subgroup analyses will be sought, as
281 appropriate, and particular care will be taken when interpreting failure between shunt
282 placement and endoscopic treatments, owing to contrasting patterns of failure over
283 the shorter and longer terms. A combination of dichotomous, proportion, continuous,
284 O-E, and variance meta-analyses are planned for this purpose, as appropriate,
285 depending on the data, and may include a potential subgroup analysis of the primary
286 outcome into short-term rates and long-term rates. Recognising that case reports may
287 present unusual and/or protracted outcomes, and randomised trials may assess active
288 interventions improving outcomes, analyses by study design are also planned.

289

290 **Strength of body of evidence**

291 The confidence in cumulative evidence included in this review will be assessed using
292 the GRADE approach. Two independent reviewers will use the GRADEpro Guideline
293 Development Tool (GRADEpro GDT) to assess the quality of outcomes of this study.
294 A third reviewer (BDT, AYT, or JJP) will settle disagreements.

295

296 **Ethics and dissemination**

297 Ethics approval for this study was not applicable because this study did not involve
298 human participants. Dissemination strategies will include publication in a peer-
299 reviewed journal, oral and poster presentations at conferences, and an interactive web
300 application to facilitate interaction with the findings and promote the discussion and
301 sharing of findings on social media.

302

303 **Patient and public involvement**

304 None

305

306 **ACKNOWLEDGEMENTS**

307 We thank Moniba Korch, Brian Ou Yong Ming, and Safia Farsana Shabeer for their
308 contributions during the development and piloting of the extraction proforma.

309

310 **AUTHOR CONTRIBUTIONS**

311 BDT, AYT, and AF were responsible for conceiving the article. AF is the guarantor.
312 BDT, AYT, JJP, and CG wrote the manuscript. AE, AF, BDT, AYT, CG, ERB, JJP, and
313 SHL provided a critical appraisal of the manuscript. All authors critically revised and
314 approved the final manuscript. BDT and AYT contributed equally and are joint first
315 authors of the manuscript.

316

317 **ETHICS APPROVAL**

318 Ethics approval for this study was not applicable because this study did not involve
319 human participants.

320

321 **DATA AVAILABILITY STATEMENT**

322 All data relevant to the study are included in the article or uploaded as supplementary
323 information.

324

325 **FUNDING**

326 This work did not receive any funding.

327

328 **COMPETING INTERESTS**

329 None declared.

330 REFERENCES

331

332

333 1. Muir RT, Wang S, Warf BC. Global surgery for pediatric hydrocephalus in the
334 developing world: a review of the history, challenges, and future directions. *Neurosurg Focus.*
335 2016;41(5):E11.

336 2. Weiss HK, Garcia RM, Omiye JA, Vervoort D, Riestenberg R, Yerneni K, et al. A
337 Systematic Review of Neurosurgical Care in Low-Income Countries. *World Neurosurg X.*
338 2020;5:100068.

339 3. Kahle KT, Kulkarni AV, Limbrick DD, Jr., Warf BC. Hydrocephalus in children. *Lancet.*
340 2016;387(10020):788-99.

341 4. McCarthy DJ, Sheinberg DL, Luther E, McCrea HJ. Myelomeningocele-associated
342 hydrocephalus: nationwide analysis and systematic review. *Neurosurg Focus.* 2019;47(4):E5.

343 5. Oumer M, Taye M, Aragie H, Tazebew A. Prevalence of Spina Bifida among Newborns
344 in Africa: A Systematic Review and Meta-Analysis. *Scientifica (Cairo).* 2020;2020:4273510.

345 6. Njamnshi AK, Djientcheu Vde P, Lekoubou A, Guemse M, Obama MT, Mbu R, et al.
346 Neural tube defects are rare among black Americans but not in sub-Saharan black Africans:
347 the case of Yaounde - Cameroon. *J Neurol Sci.* 2008;270(1-2):13-7.

348 7. Lo A, Polšek D, Sidhu S. Estimating the burden of neural tube defects in low- and
349 middle-income countries. *J Glob Health.* 2014;4(1):010402.

350 8. Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H, Mulinare J, et al. Describing
351 the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. *PLoS One.*
352 2016;11(4):e0151586.

353 9. Ntimbani J, Kelly A, Lekgwara P. Myelomeningocele - A literature review.
354 *Interdisciplinary Neurosurgery.* 2020;19:100502.

355 10. de Paul Djientcheu V, Njamnshi AK, Wonkam A, Njiki J, Guemse M, Mbu R, et al.
356 Management of neural tube defects in a Sub-Saharan African country: the situation in
357 Yaounde, Cameroon. *J Neurol Sci.* 2008;275(1-2):29-32.

358 11. Dewan MC, Rattani A, Mekary R, Glancz LJ, Yunusa I, Baticulon RE, et al. Global
359 hydrocephalus epidemiology and incidence: systematic review and meta-analysis. *J*
360 *Neurosurg.* 2018:1-15.

361 12. Mnguni MN, Enicker BC, Madiba TE. A perspective in the management of
362 myelomeningocele in the KwaZulu-Natal Province of South Africa. *Childs Nerv Syst.*
363 2020;36(7):1521-7.

364 13. Ben-Israel D, Mann JA, Yang MMH, Isaacs AM, Cadieux M, Sader N, et al. Clinical
365 outcomes in pediatric hydrocephalus patients treated with endoscopic third ventriculostomy
366 and choroid plexus cauterization: a systematic review and meta-analysis. *J Neurosurg Pediatr.*
367 2022:1-13.

368 14. Pande A, Lamba N, Mammi M, Gebrehiwet P, Trenary A, Doucette J, et al. Endoscopic
369 third ventriculostomy versus ventriculoperitoneal shunt in pediatric and adult population: a
370 systematic review and meta-analysis. *Neurosurg Rev.* 2021;44(3):1227-41.

371 15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
372 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj.*
373 2021;372:n71.

374 16. World Bank Data Help Desk. World Bank Country and Lending Groups 2022 [Available
375 from: [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
376 [country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)].

- 377 17. Rayyan. Rayyan – Intelligent Systematic Review 2022 [Available from:
378 <https://www.rayyan.ai/>.
379 18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
380 revised tool for assessing risk of bias in randomised trials. *Bmj*. 2019;366:l4898.
381 19. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al.
382 ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *Bmj*.
383 2016;355:i4919.
384 20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
385 simple, graphical test. *Bmj*. 1997;315(7109):629-34.
386 21. Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and
387 recommendations based on a large database of meta-analyses. *Medicine (Baltimore)*.
388 2019;98(23):e15987.
389 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*.
390 1986;7(3):177-88.
391 23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
392 analyses. *Bmj*. 2003;327(7414):557-60.
393